aromasil has been researched along with Genital Diseases, Female in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, JM; Fontein, DB; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kranenbarg, EM; Markopoulos, C; Nortier, JW; Paridaens, RJ; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van de Water, W; Vannetzel, JM | 1 |
1 other study(ies) available for aromasil and Genital Diseases, Female
| Article | Year |
|---|---|
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Genital Diseases, Female; Humans; International Cooperation; Middle Aged; Multicenter Studies as Topic; Musculoskeletal Diseases; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Vasomotor System | 2013 |